A focused copper-peptide serum for scalp + hair. Nothing unnecessary.
Formula, object and identity — reduced to what earns its place.
Frosted ivory. Champagne gold. The AO signature.
60 mL · current first-release concept
AUREVÉ starts with one object, not a catalogue. The serum comes first; everything else has to justify its place.
GHK-Cu has the broader research history. AHK-Cu has early hair-follicle laboratory findings. Neither is presented here as proof that the unfinished AUREVÉ serum regrows hair.
Studied across cell, animal and some human research for processes associated with extracellular matrix, fibroblasts and tissue repair. Direct hair-specific human evidence remains limited.
A 2007 ex-vivo / in-vitro study reported increased follicle elongation and dermal papilla-cell proliferation at selected concentrations. That is laboratory evidence, not a clinical regrowth result.
AUREVÉ is being built around one principle: every layer should feel considered — formula, object, language and experience.
The AO monogram works as a founders’ signature without putting either founder’s name on the front of the brand.
Explore the first serum and the intentionally unannounced slots reserved for future AUREVÉ releases.
Enter the shopOne developed release. Three spaces left intentionally open.
Copper Peptide Scalp + Hair Serum · 60 mL
Product category intentionally unannounced.
Reserved for the next considered addition.
No category or claims assigned yet.
Because AUREVÉ does not need a fictional catalogue to look established. The current collection shows the real first product direction and leaves future releases genuinely open until the founders decide what belongs.
A refined scalp + hair serum concept built around two copper-binding peptides. The finished production formula, concentrations, final INCI list and product-level efficacy claims remain subject to verification before launch.
The pairing is a formulation concept, not a clinical conclusion. Each peptide brings a different research history; the finished serum still has to stand on its own evidence.
More extensively discussed in skin, extracellular-matrix and tissue-remodelling research.
Smaller evidence base, including early ex-vivo / in-vitro work using human hair follicles and dermal papilla cells.
The production INCI list is not being guessed from supplier marketing. Until the final formula is verified, the preview stays intentionally minimal.
Copper-binding tripeptide; one of the two named peptide anchors.
Concept ingredientRelated copper-binding tripeptide with a smaller, hair-focused laboratory evidence base.
Concept ingredientVehicle, humectants, preservation and supporting ingredients to be taken from the verified production formula.
To be confirmedIngredient research informs the concept, but the site does not turn laboratory findings into finished-product promises.
GHK is a naturally occurring tripeptide that binds copper. GHK-Cu has been studied for extracellular-matrix remodelling, fibroblast activity and skin-repair biology across cell, animal and some human research. Direct hair-specific human evidence is much thinner.
AHK-Cu has a smaller published evidence base. A 2007 study using human hair follicles maintained outside the body and cultured dermal papilla cells reported increased follicle elongation and cell proliferation at selected concentrations. That is not proof of topical hair regrowth in people.
The intended format is a leave-in scalp + hair serum. Exact amount and application guidance will be published from the final product specification.
Final directions will define whether the product is applied to dry or damp scalp/hair and any relevant precautions.
The first release is designed around a simple routine rather than a catalogue of overlapping steps.
They are short copper-binding peptides. GHK-Cu has the broader research history, particularly in skin and tissue-remodelling biology. AHK-Cu has a smaller evidence base that includes laboratory work on human hair follicles and dermal papilla cells.
No. This is being developed as a cosmetic scalp + hair serum, not a proven treatment for hair loss. The finished AUREVÉ formulation has not undergone efficacy testing.
They are related but distinct copper tripeptides with different research histories. The concept is to build one focused copper-peptide formula rather than a long list of trend ingredients. The final combination and concentrations still need production verification.
The brand and product are being designed as unisex. Final suitability and precautions will follow the completed formulation and safety assessment.
Compatibility advice is intentionally not being published yet because it depends on the final formulation, packaging and validated directions.
The full INCI list will be published from the verified production formula rather than guessed from supplier marketing language.
Development preview — submissions are recorded for founders’ review.
Make fewer things. Make them considered. Never let the claim become louder than the product.
AUREVÉ is being shaped around restraint: evidence before exaggeration, identity without noise, and a range that grows only when the next product deserves to exist.
